BPC-157 – Guide complet : recherche, effets et régénération tissulaire

BPC-157 – Complete Guide: Research, Effects & Tissue Regeneration

BPC-157 – Complete Guide: Research, Effects & Tissue Regeneration

Published by Scandinavian Pen Peptide

BPC-157 (Body Protection Compound 157) is among the most extensively studied peptides in preclinical regenerative research. Derived from a protein naturally present in human gastric juice, this synthetic pentadecapeptide has attracted significant scientific interest for its tissue-protective and healing properties across multiple biological systems.

Explore our full range of research peptides or visit our Peptide FAQ. For broader context, see our peptide research guide.

What Is BPC-157?

BPC-157 is a synthetic pentadecapeptide consisting of 15 amino acids, derived from a partial sequence of the Body Protection Compound protein found in human gastric juice. Its amino acid sequence is:

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

What distinguishes BPC-157 from most biological peptides is its exceptional stability under acidic conditions. Unlike the majority of peptides, it resists degradation in the gastric environment — a property that has made it particularly relevant to gastrointestinal research and has also facilitated its study across a range of administration routes in preclinical models.

Mechanism of Action

BPC-157 engages multiple biological signalling pathways. The most well-documented mechanisms in the scientific literature include:

  • Angiogenesis — BPC-157 stimulates the formation of new blood vessels, enhancing oxygen and nutrient delivery to tissues undergoing repair.
  • Nitric oxide (NO) pathway — It modulates nitric oxide synthesis, a key vasodilatory mediator with roles in vascular protection and wound healing.
  • Growth factor expression — BPC-157 influences the upregulation of VEGF (Vascular Endothelial Growth Factor) and EGF (Epidermal Growth Factor), both central to tissue repair cascades.
  • GABAergic system — Research suggests interactions with GABAergic signalling, which may account for some of the observed effects on the central nervous system.
  • Extracellular matrix synthesis — BPC-157 stimulates collagen production and the synthesis of other extracellular matrix components essential to structural tissue repair.

See the BPC-157 mechanism studies on PubMed for the primary literature.

Musculoskeletal Regeneration Research

One of the most studied applications of BPC-157 concerns the repair and regeneration of musculoskeletal tissues. Preclinical studies have investigated its effects across several tissue types:

  • Tendons — Multiple animal model studies have reported accelerated healing of tendon injuries, including the Achilles and patellar tendons, with improved tensile strength in repaired tissue.
  • Ligaments — Comparable effects have been observed in ligament healing models, with enhanced mechanical integrity of the repaired structures.
  • Skeletal muscle — BPC-157 has demonstrated protective effects in models of induced muscle injury, with evidence of reduced inflammatory response and faster functional recovery.
  • Bone — Studies suggest a positive influence on fracture healing and bone metabolism, though the mechanisms are still being characterised.
  • Cartilage — Preliminary investigations are evaluating BPC-157’s potential role in articular cartilage regeneration, an area of considerable unmet need in current research.

For a related compound with complementary musculoskeletal research, see our TB-500 research guide.

Gastrointestinal Research

Given its origin in gastric juice, the gastrointestinal effects of BPC-157 are among the most thoroughly documented in preclinical literature:

  • Gastroprotection — BPC-157 has demonstrated significant protective effects in animal models of gastric ulceration induced by aspirin, ethanol, and psychological stress.
  • Inflammatory bowel conditions — Studies have assessed its effects in models of colitis and Crohn’s-like disease, with evidence of mucosal healing and reduced inflammatory markers.
  • Intestinal fistula — Research suggests potential application in fistula healing, including models of gastrointestinal anastomosis.
  • Gut motility — BPC-157 appears to exert a normalising influence on gastrointestinal motility in several experimental models.

See BPC-157 gastrointestinal studies on PubMed.

Neurological Research

Preclinical studies have extended the investigation of BPC-157 into the nervous system:

  • Neuroprotection — Protective effects have been observed in models of traumatic brain injury and spinal cord damage, with evidence of reduced neuronal loss and improved functional outcomes.
  • Peripheral nerve regeneration — Studies suggest potential for functional recovery following peripheral nerve injury, including sciatic nerve transection models.
  • Behavioural research — BPC-157 has been evaluated in animal models of anxiety and depressive-like behaviour, with results suggesting modulation of relevant neurotransmitter systems.

All original publications are accessible via PubMed — search “BPC-157 neuroprotection”.

BPC-157 and TB-500: Complementary Research Tools

BPC-157 and TB-500 (Thymosin Beta-4) are frequently studied together in regenerative research. While BPC-157 acts primarily through angiogenesis and growth factor upregulation, TB-500 operates via actin regulation and cell migration. Their mechanisms are distinct but complementary, which is why researchers often investigate them in combination for musculoskeletal and wound healing applications.

Safety Profile in Preclinical Research

BPC-157 has demonstrated a favourable safety profile across preclinical studies. Reported adverse effects have been mild and transient, including mild nausea, transient dizziness, and local reactions at the site of administration.

It is important to note that the substantial majority of BPC-157 research remains preclinical. Controlled human clinical trial data is limited, and no regulatory approvals for therapeutic use have been granted. This distinction matters when evaluating the strength of the evidence.

Storage Recommendations

BPC-157 should be stored at 2–8°C, protected from light and moisture. For long-term storage, −20°C is recommended. Avoid repeated freeze-thaw cycles, which can degrade peptide integrity. Lyophilized powder is significantly more stable than reconstituted solution. All Scandinavian Pen Peptide orders ship in temperature-controlled refrigerated packaging.

Summary

BPC-157 occupies a distinctive position in preclinical research. Its multi-pathway mechanism of action, combined with documented effects across musculoskeletal, gastrointestinal, and neurological systems, makes it one of the more versatile research compounds currently under investigation.

While the translation of preclinical findings to human clinical data remains an active area of development, the volume and consistency of existing research position BPC-157 as a compound of considerable scientific interest — particularly for researchers working in regenerative biology, gastroenterology, and neurotrauma.

For related compounds, see our guides on TB-500 and Ipamorelin, or browse our full peptide research guide.

⚠️ Research use only. BPC-157 is supplied by Scandinavian Pen Peptide strictly for scientific research purposes. It is not intended for human use. For any health-related questions, consult a qualified medical professional. Visit our FAQ, contact us, or see our distributor page.

Scandinavian Pen Peptide — Precision peptides for serious research.

Back to blog

The information has been compiled from various studies and analyses conducted over the years and is not intended to diagnose, treat, or prevent any diseases.